Cerebras is seeking to go public at a valuation of about $8 billion. There are several red flags why I won't invest in its ...

In a report released on October 10, David Evans from Kepler Capital maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), ...

We recently published an article titled Jim Cramer on Super Micro Computer and Other Stocks. In this article, we are going to ...

United Kingdom equities were higher at the close on Friday, as gains in the FTSE 350 Mining, FTSE 350 Household Goods and ...

GSK settles 93% of Zantac lawsuits with a $2.2 billion payout, easing investor concerns. However, doubts over its future ...

John Maraganore, the former CEO of Alnylam Pharmaceuticals, launched City Therapeutics, a new startup with $135 million from ...

Sanofi is nearing the sale of its consumer health business to Clayton Dubilier & Rice, a year after Chief Executive Officer Paul Hudson announced plans to split off the division to concentrate on ...

There’s about 270 different viruses that can infect humans, and in the fall and winter we're inside more where they can ...

Sanofi has stopped a phase 2 trial of Denali Therapeutics-partnered oditras | Sanofi has stopped a phase 2 trial of the ...

PARIS (Reuters) -Sanofi has entered into talks to sell a controlling 50% stake in its consumer health business Opella to U.S.

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

As one of the largest pharmaceutical and vaccine companies, GSK has used its vast resources to create the next generation of healthcare treatments. The company's innovative new product lineup and ...